Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

CITY-RBP4

Oligonucleotide (siRNA) · Gene silencing: retinol binding protein 4 (RBP4) · developed by City Therapeutics

Phase 1 Most advanced trial
CTY Developer
1 Registered trials

What is CITY-RBP4?

CITY-RBP4 is a small interfering RNA (siRNA) given by subcutaneous injection, designed to lower production of retinol binding protein 4 (RBP4). It is being studied in Stargardt disease 1 and in healthy volunteers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Oligonucleotide (siRNA)
Targets
retinol binding protein 4 (RBP4)
Mechanism
Gene silencing: retinol binding protein 4 (RBP4)
Therapy area
Ophthalmology
Developer
City Therapeutics (CTY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07836452 Phase 1 Stargardt Disease 1 Recruiting CTY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy VolunteersStargardt Disease 1STGD1

More from City Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the CTY page.

Follow CTY, the company behind CITY-RBP4

See CTY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CTY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.